Table 1.
EORTC QLQ-C30 and QLQ-LC13 scores at baseline.
| Baseline score | Furmonertinib (n = 178) |
Gefitinib (n = 179) |
||
|---|---|---|---|---|
| Mean | SD | Mean | SD | |
| EORTC QLQ-C30 | ||||
| HRQoL | 64.4 | 21.0 | 63.7 | 20.9 |
| Physical functioning | 87.9 | 16.3 | 85.8 | 15.2 |
| Role functioning | 90.2 | 20.2 | 88.6 | 19.0 |
| Emotional functioning | 88.4 | 13.1 | 87.7 | 14.0 |
| Cognitive functioning | 91.4 | 12.6 | 91.7 | 13.5 |
| Social functioning | 83.9 | 22.5 | 82.0 | 21.7 |
| Fatigue | 19.7 | 21.7 | 22.4 | 16.9 |
| Nausea/vomiting | 4.8 | 12.3 | 3.9 | 10.5 |
| Pain | 17.4 | 20.2 | 22.1 | 20.6 |
| Dyspnoea | 17.0 | 24.1 | 17.3 | 19.8 |
| Insomnia | 16.7 | 24.9 | 16.9 | 22.7 |
| Appetite loss | 12.2 | 21.4 | 11.2 | 18.3 |
| Constipation | 6.4 | 15.3 | 7.3 | 15.9 |
| Diarrhoea | 2.1 | 8.0 | 2.6 | 9.6 |
| Financial difficulties | 34.1 | 31.7 | 35.0 | 32.8 |
| EORTC QLQ-LC13 | ||||
| Dyspnoea | 19.8 | 19.5 | 20.7 | 19.7 |
| Cough | 33.9 | 24.9 | 30.9 | 29.6 |
| Haemoptysis | 3.7 | 11.1 | 3.4 | 12.3 |
| Sore mouth | 3.6 | 13.5 | 3.2 | 11.0 |
| Dysphagia | 4.5 | 16.0 | 3.7 | 12.7 |
| Peripheral neuropathy | 7.9 | 17.0 | 11.9 | 21.4 |
| Alopecia | 5.2 | 12.7 | 4.7 | 12.6 |
| Chest pain | 20.2 | 25.9 | 19.0 | 23.2 |
| Pain in arm or shoulder | 15.0 | 22.7 | 19.6 | 26.1 |
| Pain in other parts | 16.7 | 23.4 | 22.7 | 25.8 |
Each scale/item score range is 0–100, where higher scores indicated better functioning or HRQoL in those scales and more/worse symptoms in the symptom scale.
EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30; EORTC QLQ-LC13, European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire Lung Cancer 13; SD, standard deviation; HRQoL, health-related quality of life.